Appendix Table C19. Clinical outcomes (outcomes part A), ACEI plus ARB versus ACEI or ARB trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **All-cause Mortality****n/N (%)** | **Cardiovascular Mortality****n/N (%)** | **Myocardial Infarction,****Any n/N (%)** | **Myocardial Infarction,****Fatal n/N (%)** | **Myocardial Infarction,****Non-fatal n/N (%)** | **Stroke or CVA, Any****n/N (%)** |
| ***ACEI plus ARB versus ACEI trials (n=5)*** |
|  | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** | **ACEI+ARB** | **ACEI** |
| Sengul, 200620 |  |  |  |  |  |  |  |  |  |  |  |  |
| Menne, 200819 VALERIA | 0/43(0) | 1/47(2.1) |  |  |  |  |  |  |  |  |  |  |
| Mann ,200818 ON-TARGET |  |  |  |  |  |  |  |  |  |  |  |  |
| Kanno, 200644 |  |  |  |  |  |  |  |  |  |  |  |  |
| Mehdi, 200945 | 1/26 (3.8) | 0/27 (0.0) |  |  |  |  |  |  |  |  |  |  |
| Anand, 200946 | 362/1477 (24.5) | 341/1439 (23.7) |  |  |  |  |  |  |  |  |  |  |
| ***ACEI plus ARB versus ARB trials (n=3)*** |
|  | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** | **ACEI+ARB** | **ARB** |
| Sengul, 200620 |  |  |  |  |  |  |  |  |  |  |  |  |
| Menne, 200819 VALERIA | 0/43(0) | 0/43(0) |  |  |  |  |  |  |  |  |  |  |
| Mann, 2008 18ON-TARGET |  |  |  |  |  |  |  |  |  |  |  |  |
| ***ACEI plus ARB versus ACEI or ARB (monotherapy) trials (n=1)*** |
|  | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** | **ACEI+ARB** | **Mono** |
| Tobe 201135Mann, 2008 18ON-TARGET | 520/2943(17.7) | 1033/5990(17.2) | 317/2943(10.8) | 654/5990(11.0) |  |  |  |  |  |  |  |  |

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CVA = cerebrovascular accident
\*reported for the overall participants but not for the CKD subgroup